The problem, the consequences, and rapid testing solutions

Each year, influenza (flu) causes serious infection and death around the globe, usually in the winter months (seasonal influenza). Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 290,000 to 650,000 respiratory deaths.1


Influenza symptoms are similar to those of other common respiratory infections. Patients presenting with these symptoms are commonly treated empirically, without a formal diagnosis. 

The problem in relation to antimicrobial stewardship is twofold. Patients with Influenza-Like Illness (ILI), a medical diagnosis based on symptoms alone, are often treated with antibiotics, even though the most common cause for this set of symptoms is influenza, a viral infection. Antibiotics are not effective against viruses.

Alternatively, these patients are often automatically prescribed with influenza antivirals, which will be unnecessary if influenza is not the cause of infection and are only effective if prescribed within 48 hours of onset of symptoms.

influenza-flu img


Resistance to influenza anitivirals is emerging. Many strains of influenza have already developed resistance to the older class of flu antivirals, the adamantanes. After five decades of effective use in the prophylaxis and treatment of influenza, global resistance to these drugs has increased significantly in recent years.2

The new class of influenza antivirals, neuraminidase inhibitors, oseltamivir (Tamiflu) and zanamivir (Relenza), are currently suitable for all strains. Resistance to oseltamivir continues to increase worldwide but specific frequencies vary by geographical regions and population densities, with densely populated countries such as the United States, China and South Africa showing significant oseltamivir resistance.3


By testing patients and providing results quickly, antibiotics can be withheld and antivirals can be prescribed only where appropriate. Physician awareness of a rapid diagnosis of influenza decreases antibiotic use.4

influenza-flu img

ID NOW™ Influenza A & B 2 is a molecular flu test which provides accurate results in less than 13 minutes on the ID NOW platform. Significantly faster than other molecular methods and more accurate than conventional rapid testing, ID NOW Influenza A & B 2 enables you to deliver actionable flu results to your patients in any setting and empowers the appropriate use of antibiotics and antivirals. 

Abbott also offers a range of lateral flow tests to aid in the rapid diagnosis of flu, including BinaxNOW®Clearview® and Bioline; all excellent tools for determining those who require treatment.

View References

  1. WHO Influenza (Seasonal) Fact Sheet. Accessed on 12 Oct 22.
  2. He, W. et al. Distribution and evolution of H1N1 influenza A viruses with adamantanes‐resistant mutations worldwide from 1918 to 2019. Journal of Medical Virology 2020. 93, 3473-3483.
  3. Zhang, W. et al. Frequency and distribution of H1N1 influenza A viruses with oseltamivir‐resistant mutations worldwide before and after the 2009 pandemic. Journal of Medical Virology 2022. 94, 4406-4416.
  4. Tillekeratne, L.G. et al. Use of Rapid Influenza Testing to Reduce Antibiotic Prescriptions among Outpatients with Influenza-Like Illness in Southern Sri Lanka. American Journal of Tropical Medicine and Hygiene 2015. 93, 1031–1037.
Sign up for our newsletter to stay up to date with the latest information on antimicrobial resistance

© 2023 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. Products available in select markets only.

This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.

Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. The companies, websites, products and services, and brands referenced and linked to from this website are not sponsored or endorsed by, or otherwise affiliated with, Abbott or GDPR StatementInterest-Based Ads.

The third-party trademarks, products and services referenced and linked to from this website are included for informational purposes only, and have not been tested or approved by Abbott or Neither Abbott nor make any representations or warranties regarding third-party products or services, and shall not be liable for any claims arising from those products or services or your use thereof. See the Website Terms and Conditions for additional details.

Please click "Accept Sale/Sharing and Targeted Advertising" to enable full site functionality.

At this time, we are experiencing problems with broken links on our site. As an interim solution, for full site functionality you must enable functional and advertising cookies. If you continue to opt-out of these cookies, some content on our site may not be viewable.

We use functional cookies to analyze your use of the site, improve performance and provide a better customer experience. We use advertising cookies to allow us, through certain data assigned and obtained from the user's device, to store or share with third parties information related to user's browsing activity in our website, in order to create an advertising profile and place relevant advertising in our website or those third parties websites. For more information about how Abbott uses cookies please see our Cookie Policy and Privacy Policy.

In order to accept functional and advertising cookies, please click "Enable Cookies" and then click "Accept Sale/Sharing and Targeted Advertising" to view the full site.

Learn more about cookies